Research Article

Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Table 3

Survival outcomes according to the factors exhibiting independent prognostic value in multivariate analyses.

SurvivalN0 ()N1 () valueCA 19-9 ≤90 U/m/L ()CA 19-9 >90 U/mL () valueSIRI <1.6 ()SIRI ≥1.6 () value

OS
 Median, mo21.410.60.01120.313.70.01628.612.6<0.001
 2-year (%)43.914.244.827.451.018.2
 4-year (%)26.610.728.518.635.111.8
PFS
 Median, mo12.46.30.01810.25.80.02213.86.7<0.001
 2-year (%)27.27.829.414.632.19.7
 4-year (%)15.35.716.27.717.15.8

Abbreviations: N0/1: nodal stage 0/1; CA 19-9: cancer antigen 19-9; SIRI: systemic inflammation response index; OS: overall survival; PFS: progression-free survival.